Tag: HAV

biologics

Human Acellular Vessel Biologics License Application granted priority review by US...

Humacyte has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to Humacyte’s Biologics License Application (BLA) seeking...
biologics

Humacyte submits Biologics License Application to US FDA seeking approval of...

Humacyte today announced that it has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of the...
biologics

Humacyte announces positive top line results from Phase 2/3 trial of...

Humacyte has announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair. A...
biologics

Clinical performance of Human Acellular Vessel amid war in Ukraine presented...

Clinical outcomes of Humacyte's investigational Human Acellular Vessel (HAV) were presented at the recent Military Health System Research Symposium (14–17 August, Kissimmee, USA), following...
Ukraine

Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel...

Humacyte today announced completion of enrolment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA)...
Humacyte

Humacyte publish six-year outcomes in study of HAV for peripheral arterial...

Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced...